Gland Pharma Limited specializes in the production of sterile injectable formulations, including vials, ampoules, pre-filled syringes, and lyophilized products. The company’s focus on sterile injectables positions it as a key player in critical care, oncology, ophthalmology, and other therapeutic areas. Gland Pharma’s state-of-the-art manufacturing facilities adhere to international quality standards, ensuring the production of high-quality and safe pharmaceutical products.
- Gland Pharma Limited reported Total Income for Q4 FY23 of ₹823.95 Crore down from ₹1,168.24 Crore year on year, a decline of 29.5%.
- Total Expenses for Q4 FY23 of ₹656.33 Crore down from ₹787.76 Crore year on year, a decline of 16.7%.
- Consolidated Net Profit of ₹78.68 Crore, down 72.5% from ₹285.90 Crore in the same quarter of the previous year.
- The Earnings per Share is ₹4.78, from ₹17.36 in the same quarter of the previous year.